Navigation Links
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
Date:3/5/2008

Year marked by strengthened leadership team and the initiation of Phase 3

program for cetrorelix in BPH

All amounts are in U.S. dollars

QUEBEC CITY, March 5 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), a global biopharmaceutical company focused on endocrinology and oncology, today reported financial and operating results for the fourth quarter and full year ended December 31, 2007.

David J. Mazzo, Ph.D., Aeterna Zentaris' President and Chief Executive Officer commented, "2007 was a challenging year; a year marked by important changes to both our corporate structure and business plan. The result has given our stakeholders a sharper image of our objectives and ongoing priorities. 2007 also involved a great deal of groundbreaking, marking for example, the first time our team launched an international Phase 3 program as is the case for cetrorelix in BPH. Another first was the opening of our offices in New Jersey as part of our strategy to gain more exposure with the pharmaceutical and financial communities in the United States. Furthermore, following the appointment of three new key executives during the year, we now have a team of the highest level in clinical research, regulatory affairs, business development, pharmaceutical discovery, development and commercialization - vital assets for the successful pre-launch activities for cetrorelix, as well as for the thrust of our entire pipeline.

Moving forward, we will continue to strive to expose the depth, breadth and potential of our robust pipeline and will diligently execute our business plan with the primary objective of creating value for our shareholders."

CONSOLIDATED RESULTS FOR THE FOUR
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
2. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
3. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
4. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
7. AEterna Zentaris Announces Outcome of Managements Strategic Review
8. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
9. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
10. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
11. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 The new , Healthcare and ... available today on PharmaBoardroom.com for free download ... rocked the Spanish economy in 2009, and the austerity measures ... remained pragmatic in times of trouble. "Despite the ... biggest European market, and the general conditions to invest are ...
(Date:9/18/2014)... 18, 2014 A novel robotic system ... scanner is currently being tested as part of a ... in Boston with the aim of determining if the ... prostate cancer biopsies faster, more accurate, less costly, and ... has the potential to deliver prostate cancer therapies with ...
(Date:9/18/2014)... Research and Markets has announced the addition ... Report, 2014-2017" report to their offering. ... differentiate into specialized cells and can divide (through mitosis) ... be applied to treatment of cardiovascular diseases, leukemia (a ... or lesion of liver, kidney and other parenchymal organs, ...
(Date:9/18/2014)... , Sept. 18, 2014  U.S. biotech company ... signing an exclusive license for technology developed by the ... gene expression in plants, including for applications in production ... The technology was developed under the direction ... at Kultevat and former president of the Danforth Plant ...
Breaking Biology Technology:PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6Global and Chinese Stem Cell Industry Report, 2014-2017 2Global and Chinese Stem Cell Industry Report, 2014-2017 3Kultevat obtains license of gene switch technology 2
...  Ambit Biosciences today announced that Michael A. Martino, Ambit,s president ... company and an update about its clinical development programs, including ... in New York City. , 14th Annual BIO ... on Monday, February 13, 2012 , Leerink Swann ...
... 9, 2012  Micross Components, a leading global provider ... to announce its participation in the "Drive for ... Electronics. Included as a "pit stop" during the ... selected because of its role in powering innovation ...
... Inc. (NYSE Amex: CUR ) announces that President ... BIO CEO & Investor Conference 2012 in New York City ... present a business overview, and an update on the company,s ... divisions. (Logo:  http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) ...
Cached Biology Technology:Ambit Biosciences to Present at Two Upcoming Investor Conferences 2Micross Components Hosts Stop on "Drive for Innovation" Tour 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 2Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012 3
(Date:9/18/2014)... September 18, 2014 New research into the Crimean-Congo ... a severe hemorrhagic disease in humans similar to that ... for CCHFV infection. This discovery has the potential to ... pathogen. , The research, reported in a ... and conducted by scientists at the Texas Biomedical ...
(Date:9/18/2014)... foliage season that prompts millions of Americans to undertake jaunts ... possibly last a little longer within a century, according to ... in some areas of the United States as summer temperatures ... the journal Global Ecology and Biogeography . For instance, ... the state tree of New Hampshire could change color ...
(Date:9/18/2014)... 2014Many Americans across racial and ethnic groups describe ... on their day-to-day life, more so than other ... speech (57% of African-Americans, 49% of non-Hispanic whites, ... asked which disease or ailment is the worst ... among African-Americans followed by AIDS/HIV. Hispanics and ...
Breaking Biology News(10 mins):Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... person or set of identical twins. That makes them ... to international travel. But what happens when the tips ... ridges? It,s not the premise for a ... adermatoglyphia. It,s also known as "Immigration Delay Disease," because ...
... Scientists at the University of Plymouth have shown, for the ... effect on the brain and other parts of the central ... nanoparticles which are widely used as a whitening agent in ... applications being considered for the food industry. They found that ...
... common medicines on elderly people were widely reported earlier in the ... not appear to cause further cognitive impairment in those already suffering ... today by the journal Age and Ageing , Dr Chris ... a number of other universities and the NHS describe how they ...
Cached Biology News:Shake hands with the invisible man 2Reassurance for dementia sufferers on impact of common drugs 2
... Time-resolved microscopy is the ultimate tool for ... structures. Its applications previously have been limited ... microscope optics do not transmit in the ... in fluorescence spectroscopy, introduces a filter-based confocal ...
... G bind specifically to Fc regions of ... G conjugates are commonly used as affinity ... subtypes from serum, hybridoma ascites fluids, tissue ... reagents are also commonly used to capture ...
... quick (10 min) assay can detect H2O2 ... 10-acetyl-3,7-dihydroxyphenoxazine (ADHP). H2O2 oxidizes ADHP in a ... resorufin (excitation at 530-571 nm, emission at ... peroxidase in a one-step, homogeneous, no wash ...
... The Reverse-iT™ One-Step Kit is the ... in RT-PCR. It has been specifically ... The Reverse-iT™ One-Step Kit combines ... and ABgene®s Thermoprime Plus DNA Polymerase ...
Biology Products: